Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul H Berg

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
The American Journal of Psychiatry|October 4, 2005
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophreniaAlan Breier, Paul H Berg, Jogin H Thakore, et al.
JAMA|August 28, 2023
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical TrialStephen J Nicholls, Steven E Nissen, Cynthia Fleming, et al.
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|August 22, 2022
Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19Rosie S Jones, Patricia S Smith, Paul H Berg, et al.
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|December 19, 2022
Erratum: ErratumRosie S Jones, Patricia S Smith, Paul H Berg, et al.
Journal of the American Society of Nephrology : JASN|September 21, 2016
Anti-TGF-<i>β</i>1 Antibody Therapy in Patients with Diabetic NephropathyJames Voelker, Paul H Berg, Matthew Sheetz, et al.
British Journal of Clinical Pharmacology|January 25, 2019
Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney diseaseMatthew Sheetz, Philip Barrington, Sophie Callies, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
The American Journal of Psychiatry|October 4, 2005
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophreniaAlan Breier, Paul H Berg, Jogin H Thakore, et al.
JAMA|August 28, 2023
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical TrialStephen J Nicholls, Steven E Nissen, Cynthia Fleming, et al.
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|August 22, 2022
Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19Rosie S Jones, Patricia S Smith, Paul H Berg, et al.
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|December 19, 2022
Erratum: ErratumRosie S Jones, Patricia S Smith, Paul H Berg, et al.
Journal of the American Society of Nephrology : JASN|September 21, 2016
Anti-TGF-<i>β</i>1 Antibody Therapy in Patients with Diabetic NephropathyJames Voelker, Paul H Berg, Matthew Sheetz, et al.
British Journal of Clinical Pharmacology|January 25, 2019
Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney diseaseMatthew Sheetz, Philip Barrington, Sophie Callies, et al.
Pageof 2